Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PST021
MIFTS: 50

Postpartum Depression

Categories: Mental diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Postpartum Depression

About this section

MalaCards integrated aliases for Postpartum Depression:

Name: Postpartum Depression 11 41 14 16 75
Depression, Postpartum 43 71
Postnatal Depression 11 14
Maternity Blues 11 71
Post-Partum Depression 75
Depression Postpartum 53

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:9478
MeSH 43 D019052
NCIt 49 C92852
SNOMED-CT 68 58703003
ICD10 31 F53.0
UMLS 71 C0221074 C3251820
Sources

Summaries for Postpartum Depression

About this section

MedlinePlus: 41 Many women have the baby blues after childbirth. If you have the baby blues, you may have mood swings, feel sad, anxious or overwhelmed, have crying spells, lose your appetite, or have trouble sleeping. The baby blues most often go away within a few days or a week. The symptoms are not severe and do not need treatment. The symptoms of postpartum depression last longer and are more severe. You may also feel hopeless and worthless and lose interest in the baby. You may have thoughts of hurting yourself or the baby. Very rarely, new mothers develop something even more serious. They may have hallucinations or try to hurt themselves or the baby. They need to get treatment right away, often in the hospital. Postpartum depression can begin anytime within the first year after childbirth. The cause is unknown. Hormonal and physical changes after birth and the stress of caring for a new baby may play a role. Women who have had depression are at higher risk. If you think you have postpartum depression, tell your health care provider. Medicines, including antidepressants, and talk therapy can help you get well. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary: Postpartum Depression, also known as depression, postpartum, is related to major depressive disorder and mood disorder, and has symptoms including mental and behavioral signs and symptoms and pelvic pain. An important gene associated with Postpartum Depression is CRH (Corticotropin Releasing Hormone), and among its related pathways/superpathways are Signal Transduction and Myometrial relaxation and contraction pathways. The drugs Ethinylestradiol and Copper have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and thyroid, and related phenotypes are nervous system and homeostasis/metabolism

Disease Ontology: 11 An endogenous depression that involves intense, sustained and sometimes disabling depression experienced by women after giving birth.

Wikipedia: 75 Postpartum depression (PPD), also called postnatal depression, is a type of mood disorder associated... more...
Sources

Related Diseases for Postpartum Depression

About this section

Diseases related to Postpartum Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 380)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 31.0 TTC9B TPO SLC6A4 PRL POMC OXT
2 mood disorder 30.5 SLC6A4 POMC OXT NR3C1 MAOA IL6
3 pain agnosia 30.5 POMC PNOC OXT IL6 HTR1A CRH
4 alexithymia 30.3 SLC6A4 OXTR OXT CRH BDNF
5 acute stress disorder 30.2 SLC6A4 POMC OXT NR3C1 CRH BDNF
6 bipolar i disorder 30.2 SLC6A4 PRL HTR1A BDNF
7 bulimia nervosa 30.2 SLC6A4 OXT MAOA BDNF
8 personality disorder 30.2 SLC6A4 PRL OXTR NR3C1 MAOA HTR1A
9 bipolar disorder 30.1 SLC6A4 PRL NR3C1 MAOA IL6 HTR1A
10 thyroiditis 30.1 TPO PRL IL6
11 schizoaffective disorder 30.1 SLC6A4 PRL HTR1A BDNF
12 adult syndrome 30.1 POMC NR3C1 IL6 HSD11B2 CRH
13 eating disorder 30.1 SLC6A4 POMC OXTR OXT HTR1A CRH
14 headache 30.1 SLC6A4 PRL BDNF
15 preterm premature rupture of the membranes 30.0 OXT IL6 CRH
16 sleep disorder 30.0 SLC6A4 POMC IL6 HTR1A CRH BDNF
17 acne 30.0 PRL POMC IL6 CRH
18 asphyxia neonatorum 30.0 OXT IL6 BDNF
19 hyperthyroidism 30.0 TPO PRL POMC IL6
20 disease of mental health 30.0 SLC6A4 POMC OXTR OXT MAOA IL6
21 hyperandrogenism 29.9 PRL POMC NR3C1
22 psychotic disorder 29.9 SLC6A4 PRL OXTR OXT MAOA IL6
23 leptin deficiency or dysfunction 29.9 POMC OXT IL6 CRH BDNF
24 hypochondriasis 29.9 SLC6A4 POMC OXT MAOA HTR1A BDNF
25 anxiety 29.9 SLC6A4 PRL POMC PNOC OXTR OXT
26 generalized anxiety disorder 29.9 SLC6A4 POMC OXT MAOA IL6 HTR1A
27 alcohol use disorder 29.9 SLC6A4 POMC MAOA IL6 CRH BDNF
28 restless legs syndrome 29.8 SLC6A4 PRL POMC MAOA
29 conduct disorder 29.8 SLC6A4 POMC OXTR OXT MAOA
30 sudden infant death syndrome 29.8 SLC6A4 NR3C1 MAOA IL6 HTR1A BDNF
31 post-traumatic stress disorder 29.8 SLC6A4 POMC OXTR OXT NR3C1 MAOA
32 fragile x syndrome 29.8 SLC6A4 MAOA GABRD BDNF
33 sexual health disorder 29.8 SLC6A4 PRL OXTR OXT MAOA HTR1A
34 agoraphobia 29.8 SLC6A4 MAOA HTR1A CRH BDNF
35 acquired immunodeficiency syndrome 29.8 POMC NR3C1 IL6 CRH
36 panic disorder 29.8 SLC6A4 PRL POMC MAOA IL6 HTR1A
37 adjustment disorder 29.7 SLC6A4 POMC OXT LCOR IL6 HTR1A
38 epilepsy 29.7 POMC MAOA IL6 HTR1A GABRD BDNF
39 alcohol dependence 29.7 SLC6A4 POMC PNOC MAOA HTR1A CRH
40 diarrhea 29.7 SLC6A4 IL6 HTR1A BDNF
41 neurotic disorder 29.6 SLC6A4 POMC OXT MAOA IL6 HTR1A
42 substance abuse 29.6 SLC6A4 PRL POMC OXT MAOA IL6
43 paine syndrome 29.6 SLC6A4 POMC PNOC IL6 CRH BDNF
44 dysthymic disorder 29.5 SLC6A4 POMC OXT MAOA IL6 HTR1A
45 alzheimer disease, familial, 1 29.5 SLC6A4 OXT MAOA IL6 HTR1A CRH
46 atypical depressive disorder 29.5 SLC6A4 POMC NR3C1 MAOA IL6 HTR1A
47 somatoform disorder 29.5 SLC6A4 POMC IL6 HTR1A CRH BDNF
48 osteoporosis 29.3 PRL OXT NR3C1 IL6 HSD11B2 BDNF
49 borderline personality disorder 29.3 SLC6A4 PRL OXTR NR3C1 MAOA HTR1A
50 autism spectrum disorder 29.3 SLC6A4 OXTR OXT NR3C1 MAOA IL6

Graphical network of the top 20 diseases related to Postpartum Depression:



Diseases related to Postpartum Depression
Sources

Symptoms & Phenotypes for Postpartum Depression

About this section

UMLS symptoms related to Postpartum Depression:


mental and behavioral signs and symptoms; pelvic pain

MGI Mouse Phenotypes related to Postpartum Depression:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.13 BDNF CRH EBF1 GABRD HTR1A IL6
2 homeostasis/metabolism MP:0005376 10.13 BDNF CRH DHRS9 HP1BP3 HSD11B2 HTR1A
3 no phenotypic analysis MP:0003012 9.91 BDNF CRH DHRS9 HTR1A NR3C1 OXTR
4 behavior/neurological MP:0005386 9.86 BDNF CRH EBF1 GABRD HSD11B2 HTR1A
5 endocrine/exocrine gland MP:0005379 9.85 BDNF CRH IL6 NR3C1 OXT OXTR
6 integument MP:0010771 9.4 BDNF CRH EBF1 IL6 NR3C1 OXT
Sources

Drugs & Therapeutics for Postpartum Depression

About this section

Drugs for Postpartum Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethinylestradiol Approved Phase 4 57-63-6 5991
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3
Norethisterone Approved Phase 4 68-22-4 199472 6230
4
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
5
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
6
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
7
Calcium carbonate Approved, Investigational Phase 4 471-34-1
8
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
9
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Esketamine Approved, Investigational Phase 4 33643-46-8 182137
12
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
13
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
14
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Sertraline Approved Phase 4 79617-96-2 68617
17
Dexetimide Withdrawn Phase 4 21888-98-2 30843
18
Flurbiprofen axetil Investigational Phase 4 91503-79-6
19 Copper Supplement Phase 4
20 Spermatocidal Agents Phase 4
21
Norethindrone Acetate Phase 4 541197
22 Calcium, Dietary Phase 4
23 Anti-Ulcer Agents Phase 4
24 Antacids Phase 4
25 Gastrointestinal Agents Phase 4
26 Antineoplastic Agents, Hormonal Phase 4
27 Contraceptives, Oral, Hormonal Phase 4
28 Contraceptives, Oral Phase 4
29 Contraceptive Agents, Male Phase 4
30 Excitatory Amino Acid Antagonists Phase 4
31 Anesthetics, Dissociative Phase 4
32 Analgesics, Opioid Phase 4
33 Narcotics Phase 4
34 Dsuvia Phase 4
35 Estrogens Phase 4
36 Estradiol 3-benzoate Phase 4
37 Estradiol 17 beta-cypionate Phase 4
38 Hormones Phase 4
39 Hormone Antagonists Phase 4
40 Serotonin Uptake Inhibitors Phase 4
41
Calcium Nutraceutical Phase 4 7440-70-2 271
42
Aripiprazole Approved, Investigational Phase 3 129722-12-9 60795
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 437-38-7 3345
44
Ropivacaine Approved Phase 2, Phase 3 84057-95-4 71273 175805
45
Nitrous oxide Approved, Vet_approved Phase 2, Phase 3 10024-97-2 948
46
Meperidine Approved Phase 2, Phase 3 57-42-1 4058
47
Remifentanil Approved Phase 2, Phase 3 132875-61-7 60815
48
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
49
Iron Approved Phase 2, Phase 3 7439-89-6 29936
50 Psychotropic Drugs Phase 3

Interventional clinical trials:

(show top 50) (show all 335)
# Name Status NCT ID Phase Drugs
1 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
2 Escitalopram for the Treatment of Postpartum Depression Completed NCT00833469 Phase 4 Escitalopram
3 Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial Completed NCT03336541 Phase 4 Ketamine;Placebo
4 Effect of Tramadol in Prevention of Postpartum Depression Completed NCT03309163 Phase 4 Tramadol;Hydromorphone;Ropivacaine (Epidural analgesia)
5 Calcium for the Prevention of Postpartum Depression Completed NCT00228033 Phase 4 Elemental calcium (as carbonate)
6 Effect of Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding Continuation, Contraceptive Continuation, and Postpartum Depression: a Randomized Trial Completed NCT01463202 Phase 4 Depot medroxyprogesterone acetate
7 Assessment of Safe-use Conditions for Administration of ZULRESSO in a Home Setting Completed NCT05059600 Phase 4 ZULRESSO®
8 Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries: A Randomized Clinical Trial Recruiting NCT03470675 Phase 4 Epidural saline + IV saline;Epidural morphine 3 mg + IV saline;Epidural morphine 3 mg + IV ketamine 0.3 mg/kg
9 Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: A Prospective Double Blind Randomized Control Trial Enrolling by invitation NCT04017442 Phase 4 Preservative Free Morphine;Saline
10 Effects of Different Concentrations of Esketamine on Postpartum Depression After Cesarean Section Not yet recruiting NCT05229913 Phase 4 Esketamine is not added;Esketamine 0.2mg/kg;Esketamine 0.4mg/kg;Esketamine 0.6mg/kg;Esketamine 0.8mg/kg
11 Postpartum Depression: Transdermal Estradiol Versus Sertraline Terminated NCT00744328 Phase 4 Transdermal Estradiol;Sertraline
12 An Evaluation of Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO Withdrawn NCT04273191 Phase 4 Brexanolone
13 Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale Unknown status NCT00251342 Phase 2, Phase 3
14 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression Completed NCT02942017 Phase 3 Placebo;SAGE-547 90 μg/kg/h
15 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression Completed NCT02942004 Phase 3 Placebo;SAGE-547 60 μg/kg/h;SAGE-547 90 μg/kg/h
16 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression Completed NCT02978326 Phase 3 SAGE-217 15/20 mg Oral Solution;Placebo;SAGE 217 30 mg Capsules
17 Postpartum Depression After Cesarean Delivery: Ketamine as a Preventative Intervention: A Feasibility Pilot-study Completed NCT04227704 Phase 3 Ketamine 50 MG/ML;Control
18 A Multicenter, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Brexanolone in the Treatment of Adolescent Female Subjects With Postpartum Depression Completed NCT03665038 Phase 3 Brexanolone
19 Identification and Therapy of Postpartum Depression Completed NCT00282776 Phase 3
20 Prevention of Recurrent Postpartum Depression Completed NCT00276900 Phase 3 Sertraline
21 A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression Completed NCT04442503 Phase 3 SAGE-217;Placebo
22 A Pilot Study of Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine Completed NCT01527786 Phase 3 Desvenlafaxine
23 Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole Completed NCT01386086 Phase 3 aripiprazole
24 Improving Health Outcomes for New Mothers and Babies Completed NCT00360204 Phase 3
25 A Randomised, Controlled Evaluation of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression Completed NCT02122393 Phase 3 Sertraline
26 Effect of the 'Mother and Baby' Program on New Mothers' Psychological and Physical Well-Being. Completed NCT00361478 Phase 3
27 The SUPPORT Study: Survey and Development of a Universally Accessible Postpartum Online Resource for the Treatment of Postpartum Depression Recruiting NCT05382884 Phase 3
28 Comparison of the Role of Epidural Analgesia Versus Non-epidural Analgesia in Postnatal Depression and Persistent Pain Development: a Randomized Controlled Trial Active, not recruiting NCT03167905 Phase 2, Phase 3 Entonox;Meperidine;Ultiva;Fentanyl;Ropivacaine
29 mHealth Mindfulness Intervention for Pregnant Black and Latina Women at Risk of Postpartum Depression Enrolling by invitation NCT05186272 Phase 3
30 Resources, Inspiration, Support and Empowerment (R.I.S.E.) for Black Pregnant Women Not yet recruiting NCT05552053 Phase 2, Phase 3
31 Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression: a Randomized, Double-blind, Placebo-controlled Trial Terminated NCT02726659 Phase 3 Celecoxib;Placebo
32 A 6-week Randomised, Open Comparative, Multi-centre Study of Intravenous Ferric Carboxymaltose (Ferinject) and Oral Iron (Duroferon) for Treatment of Post Partum Anemia Terminated NCT00929409 Phase 2, Phase 3 Ferric carboxymaltose;Ferrous sulfate tablets
33 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression Completed NCT02614547 Phase 2 SAGE-547;Placebo
34 An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression Completed NCT02285504 Phase 2 SAGE-547
35 Evidence-based, Distance Treatment for Postpartum Depression, Mom: Managing Our Mood, Part of The Family Help Program Completed NCT00795652 Phase 2
36 Efficacy of an Exercise Intervention for the Prevention of PostPartum Depression Completed NCT00961402 Phase 2
37 Placebo Controlled Trial of Sertraline and Interpersonal Psycho-Therapy for Postpartum Depression Completed NCT00602355 Phase 2 Sertraline;Placebo
38 A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression Completed NCT03228394 Phase 2 Ganaxolone;Placebo
39 Repetitive Transcranial Magnetic Stimulation Effects on Clinical, Cognitive and Social Performance in Postpartum Depression Completed NCT01452321 Phase 2
40 A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression Completed NCT03460756 Phase 2 Ganaxolone;Placebo
41 Preventing Postpartum Depression in African American Home Visiting Clients Completed NCT01175603 Phase 2
42 Evaluation of PK/PD, Breastmillk Transfer, and Effectiveness of Ketamine After Cesarean Delivery - Part 1 Completed NCT04037085 Phase 2 Ketamine
43 Randomized Controlled Trial of Omega-3 Fatty Acids for Perinatal Depression Completed NCT00402389 Phase 2 Omega-3 Fatty Acids (EPA plus DHA);Placebo
44 Depression Intervention for Financially Disadvantaged Pregnant Women. Completed NCT00601757 Phase 2
45 Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model Completed NCT04051320 Phase 2 Leuprolide Acetate 3.75 MG/ML;Estradiol 2 Mg tablet;Micronized progesterone
46 Efficacy of Learning Through Play Plus Intervention to Reduce Maternal Depression for Women With Under-nourished Children: A Randomized Controlled Trial From Pakistan Completed NCT01309516 Phase 2
47 Change Your Life With Seven Sheets of Paper: A Pilot Randomized Controlled Trial for Postnatal Depression: A Pilot Randomized Controlled Trial for Postnatal Depression Completed NCT02532504 Phase 2
48 Short Time Oestrogen as a Candidate Strategy to Prevent Postpartum Depression in a High-risk Group: a Randomised, Placebo-controlled Trial. Recruiting NCT04685148 Phase 1, Phase 2 Transdermal patch estradiol;Transdermal patch placebo
49 An Endocrine Model for Postpartum Mood Disorders Recruiting NCT00001481 Phase 2 Estradiol;Progesterone
50 Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD Active, not recruiting NCT02505984 Phase 2 Oxytocin;Placebo

Search NIH Clinical Center for Postpartum Depression

Cochrane evidence based reviews: depression, postpartum

Sources

Genetic Tests for Postpartum Depression

About this section
Sources

Anatomical Context for Postpartum Depression

About this section

Organs/tissues related to Postpartum Depression:

MalaCards : Breast, Brain, Thyroid, Amygdala, Prefrontal Cortex, Spinal Cord, Pituitary
Sources

Publications for Postpartum Depression

About this section

Articles related to Postpartum Depression:

(show top 50) (show all 7947)
# Title Authors PMID Year
1
Effects of esketamine on analgesia and postpartum depression after cesarean section: A randomized, double-blinded controlled trial. 62 41
36451452 2022
2
Exercise, Mediterranean Diet Adherence or Both during Pregnancy to Prevent Postpartum Depression-GESTAFIT Trial Secondary Analyses. 62 41
36361335 2022
3
A randomized feasibility pilot-study of intravenous and subcutaneous administration of ketamine to prevent postpartum depression after planned cesarean delivery under neuraxial anesthesia. 62 41
36271352 2022
4
Premature recommendation of corticotropin-releasing hormone as screen for postpartum depression. 53 62
19652134 2009
5
[Correlative analysis of postpartum depression]. 53 62
17611326 2007
6
Clinical controversies in screening women for thyroid disorders during pregnancy. 53 62
16647667 2006
7
Cortisol response to ovine corticotropin-releasing hormone in a model of pregnancy and parturition in euthymic women with and without a history of postpartum depression. 53 62
15546899 2005
8
[Changes and significance of orphanin and serotonin in patients with postpartum depression]. 53 62
14728841 2003
9
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. 53 62
12377295 2002
10
Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. 53 62
11720875 2001
11
High-dose transdermal estrogen, corticotropin-releasing hormone, and postnatal depression. 53 62
9024283 1997
12
Neurosteroids as stress modulators and neurotherapeutics: lessons from the retina. 62
36254981 2023
13
Antenatal depressive symptoms are strongly predicted by the severity of pre-menstrual syndrome: results of partial least squares analysis. 62
36415609 2023
14
Comparison of relative areas of interest between major depression disorder and postpartum depression. 62
36341842 2023
15
Perinatal depression and serum vitamin D status: A cross-sectional study in urban China. 62
36395990 2023
16
Resveratrol alleviates postpartum depression-like behavior by activating autophagy via SIRT1 and inhibiting AKT/mTOR pathway. 62
36356720 2023
17
Prevalence of and factors associated with postnatal depression and anxiety among parents of preterm infants: A systematic review and meta-analysis. 62
36400151 2023
18
The effect of crocin versus sertraline in treatment of mild to moderate postpartum depression: a double-blind, randomized clinical trial. 62
36473029 2023
19
Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. 62
36191643 2023
20
Postpartum depression in rats causes poor maternal care and neurochemical alterations on dams and long-lasting impairment in sociability on the offspring. 62
36041571 2023
21
The impact of maternal depression, anxiety, and stress on early neurodevelopment in boys and girls. 62
36280196 2023
22
Association between depressive symptoms in the postpartum period and COVID-19: A meta-analysis. 62
36195169 2023
23
The impact of physical activity intervention on perinatal depression: A systematic review and meta-analysis. 62
36374719 2023
24
The association between maternal symptoms of depression and hair glucocorticoids in infants across the perinatal period. 62
36370678 2023
25
Traumatic experiences of the Great East Japan Earthquake and postpartum depressive symptoms: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study. 62
36191647 2023
26
The Chichewa Wijma delivery expectancy/experience questionnaire: a factor analytic study for postpartum women in Malawi. 62
36194674 2022
27
Preconception menstrual cycle disorder and antenatal depression: a cross-sectional study with prerecorded information. 62
34882063 2022
28
'Optimal' cutoff selection in studies of depression screening tool accuracy using the PHQ-9, EPDS, or HADS-D: A meta-research study. 62
36461893 2022
29
Maternal insomnia and depressive symptoms and early childhood sleep among Arab and Jewish families in Israel. 62
36122508 2022
30
Bi-dimensional acculturation and social support on perinatal depression in marriage-based immigrant women. 62
36428054 2022
31
Supporting routine cognitive reactivity assessment during the perinatal period: psychometric testing of the Chinese version of the Leiden Index of Depression Sensitivity. 62
36474194 2022
32
Correlation between primary family caregiver identity and maternal depression risk in poor rural China. 62
36473710 2022
33
Prenatal and postpartum maternal mental health and neonatal motor outcomes during the COVID-19 pandemic. 62
35873090 2022
34
Maternal postpartum depression impacts infants' joint attention differentially across cultures. 62
36107661 2022
35
Retraction Note to: The efficacy of early iron supplementation on postpartum depression, a randomized double‑blind placebo‑controlled trial. 62
36149465 2022
36
Prescribing Sleep With an Evolutionary Perspective to Prevent Postpartum Depression. 62
35662506 2022
37
Application of machine learning in predicting the risk of postpartum depression: A systematic review. 62
36055532 2022
38
The association between pregnancy intention, fertility treatment use, and postpartum depression. 62
36274452 2022
39
Risk factors for postpartum depression among sexual minority and heterosexual parents. 62
36264652 2022
40
Factors affecting postpartum depression in Turkish women. 62
36428078 2022
41
Pre-partum HRV as a predictor of postpartum depression: The potential use of a smartphone application for physiological recordings. 62
36162652 2022
42
Comparison of the chronic unpredictable mild stress and the maternal separation in mice postpartum depression modeling. 62
36191374 2022
43
Association between prenatal period exposure to ambient air pollutants and development of postpartum depression: a systematic review and meta-analysis. 62
36469809 2022
44
Maternal alcohol consumption and risk of postpartum depression: a meta-analysis of cohort studies. 62
36423494 2022
45
Experiences of Postpartum Depression of Women of Color. 62
36472495 2022
46
Is it reciprocating or self-serving?: Understanding coping strategies for postpartum depression in an online community for Korean mothers. 62
35195498 2022
47
Many or too many progesterone membrane receptors? Clinical implications. 62
36384863 2022
48
Psychiatric Manifestations of Withdrawal Following Domperidone Used as a Galactagogue. 62
36367713 2022
49
Relationship between Perceived Quality of Prenatal Care and Maternal/Infant Health Outcomes. 62
36455897 2022
50
Postpartum bonding: the impact of stressful life events during pregnancy. 62
34187270 2022
Sources

Variations for Postpartum Depression

About this section
Sources

Expression for Postpartum Depression

About this section
Search GEO for disease gene expression data for Postpartum Depression.
Sources

Pathways for Postpartum Depression

About this section

Pathways related to Postpartum Depression according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.52 POMC PNOC OXTR OXT NR3C1 IL6
2
Myometrial relaxation and contraction pathways 74
Show member pathways
 12.26 OXTR OXT IL6 CRH
3
Interleukin-4 and Interleukin-13 signaling 66
11.7 POMC MAOA IL6
4
Glucocorticoid receptor regulatory network 61
11.34 PRL POMC NR3C1 IL6
5
Sudden infant death syndrome (SIDS) susceptibility pathways 74
11.3 SLC6A4 NR3C1 MAOA IL6 HTR1A BDNF
6
Prader-Willi and Angelman syndrome 74
11.03 POMC OXT GABRD BDNF
7
Serotonin and anxiety 74
Show member pathways
 11.01 CRH HTR1A POMC
8
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.94 SLC6A4 MAOA HTR1A
9
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.79 SLC6A4 MAOA HTR1A
10
Vasopressin-like receptors 66
Show member pathways
 10.5 OXTR OXT
11
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.28 POMC CRH
Sources

GO Terms for Postpartum Depression

About this section

Biological processes related to Postpartum Depression according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 PRL POMC PNOC OXTR OXT NR3C1
2 response to glucocorticoid GO:0051384 10.02 OXT IL6 HSD11B2
3 positive regulation of synapse assembly GO:0051965 10.01 OXTR OXT BDNF
4 social behavior GO:0035176 9.99 SLC6A4 OXTR OXT
5 memory GO:0007613 9.97 BDNF OXT OXTR SLC6A4
6 positive regulation of uterine smooth muscle contraction GO:0070474 9.83 OXTR OXT
7 glucocorticoid metabolic process GO:0008211 9.8 HSD11B2 NR3C1
8 negative regulation of gastric acid secretion GO:0060455 9.78 OXTR OXT
9 positive regulation of penile erection GO:0060406 9.76 OXTR OXT
10 positive regulation of norepinephrine secretion GO:0010701 9.73 OXTR OXT
11 maternal behavior GO:0042711 9.63 NR3C1 OXT OXTR
12 response to steroid hormone GO:0048545 9.58 OXTR OXT HSD11B2
13 sperm ejaculation GO:0042713 9.43 SLC6A4 OXTR OXT
14 female pregnancy GO:0007565 9.4 PRL PNOC OXTR OXT HSD11B2 CRH
15 regulation of digestive system process GO:0044058 9.26 OXTR OXT

Molecular functions related to Postpartum Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 PRL POMC OXT CRH
2 neuropeptide hormone activity GO:0005184 9.1 PNOC OXT CRH
Sources

Sources for Postpartum Depression

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....